Hepatoma is one of the most severe malignancies usually with poor prognosis, and many patients are insensitive to the existing therapeutic agents, including the drugs for chemotherapy and molecular targeted therapy. Currently, researchers are committed to developing the advanced formulations with controlled drug delivery to improve the efficacy of hepatoma therapy. Numerous inoculated, induced, and genetically engineered hepatoma rodent models are now available for formulation screening. However, animal models of hepatoma cannot accurately represent human hepatoma in terms of histological characteristics, metastatic pathways, and post-treatment responses. Therefore, advanced animal hepatoma models with comparable pathogenesis and pathological features are in urgent need in the further studies. Moreover, the development of nanomedicines has renewed hope for chemotherapy and molecular targeted therapy of advanced hepatoma. As one kind of advanced formulations, the polymer-based nanoformulated drugs have many advantages over the traditional ones, such as improved tumor selectivity and treatment efficacy, and reduced systemic side effects. In this article, the construction of rodent hepatoma model and much information about the current development of polymer nanomedicines were reviewed in order to provide a basis for the development of advanced formulations with clinical therapeutic potential for hepatoma.
[1]Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Hosp 1, Changchun 130021, Jilin, Peoples R China.
[2]Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Jilin, Peoples R China.
[3]Chinese Acad Sci, Beijing Natl Lab Mol Sci, Inst Chem, State Key Lab Polymer Phys & Chem, Beijing 100190, Peoples R China.
[4]Jilin Biomed Polymers Engn Lab, Changchun 130022, Jilin, Peoples R China.
[5]Jilin Univ, Dept Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
(8.0+极速模式)